Diagnostic imaging and therapeutic agents to help identify and treat disease and improve patient care
Improved diagnostic information for better patient management
Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement
Lantheus Holdings to Present at the 2020 Evercore ISI HealthCONx Conference
Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY® Room Temperature
Providing you with important information regarding our response to the C0VID-19 pandemic.
(updated 5/29/2020)
View a recent Lantheus webinar:
COVID-19: Clinical Experiences from the Front Line in NYC
Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement
Lantheus Holdings to Present at the 2020 Evercore ISI HealthCONx Conference
Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY® Room Temperature
At Lantheus, we develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.
We are developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.